Accounting Pronouncements	3 Months Ended
	Jun. 30, 2023
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
New Accounting Pronouncements And Changes In Accounting Principles [Text Block]	Adoption of new Accounting Pronouncements On April 1, 2023, the Company adopted Accounting Standards Update (“ASU“) 2018-12,   Targeted Improvements to the Accounting for Long-Duration Contracts which is applicable to Oxford. The Company used the modified retrospective method applies as the transition date of April 1, 2021. The updated accounting guidance required changes to the measurement and disclosure of long-duration contracts. For the Company, this includes all life insurance products, annuities, Medicare Supplement products and our long-term care business. Entities will be required to review, and update if there is a change to cash flow assumptions (including morbidity and persistency) at least annually, and to update discount rate assumptions quarterly using an upper-medium grade fixed-income instrument yield. The effect of changes in cash flow assumptions will be recorded in the Company's results of operations and the effect of changes in discount rate assumptions will be recorded in other comprehensive income. The most significant impact will be the effect of updating the discount rate assumption quarterly to reflect an upper-medium grade fixed-income instrument yield, rather than Oxford Life’s expected investment portfolio yield. This will be partially offset by the de-recognition of cumulative adjustments to DAC associated with unrealized gains and losses associated with long-duration contracts. The Company uses a published spot rate curve constructed from “A”-rated U.S. dollar denominated corporate bonds matched to the duration of the corresponding insurance liabilities, to calculate discount rates. The Company will groups its long-duration contracts into calendar year cohorts based on the contract issue date. DAC and other capitalized costs such as unearned revenue are amortized on a constant level or straight-line basis over the expected term of the contracts. Under ASU 2018-12, the annual amortization of DAC in our Consolidated Statements of Operations will differ from previous trends due to: 1) the requirement to no longer defer renewal commissions until such year as the commissions are actually incurred, 2) the requirement to no longer accrue and amortize interest on our DAC balances, and 3) the modification of the method for amortizing DAC including the updating of assumptions. For business with deferrals of renewal commissions, as is the case with our final expense life insurance policies, the expected amortization rate, as a percentage of premium, for certain blocks of business will no longer be level but will increase over the period of time during which commissions are deferred. The decrease in amortization in the near term will primarily impact our life insurance line of business. Upon adoption, the Company made adjustments to AOCI for the removal of cumulative adjustments to DAC associated with unrealized gains and losses previously recorded in AOCI. In total, we expect the impact on net earnings, largely from the decrease in amortization, to be immaterial during fiscal 2024, but could become material with a large increase in sales. Market risk benefits, which are contracts or contract features that provide protection to the policyholder from capital market risk and expose the Company to other-than-nominal capital market risk, are measured at fair value.   Market risk benefits are contracts or contract features that guarantee benefits, such as guaranteed life withdrawal benefits, in addition to an account balance which expose insurance companies to other than nominal capital market risk and protect the contract holder from the same risk. Certain contracts or contract features to be identified as market risk benefits were accounted for as embedded derivatives and measured at fair value, while others transitioned to fair value measurement upon the adoption of ASU 2018-12. Also in consideration of market risk benefits, upon adoption, there were impacts to (1) AOCI for the cumulative effect of changes in the instrument-specific credit risk between contract issue date and transition date and (2) retained earnings for the difference between fair value and carrying value at the transition date, excluding the changes in the instrument-specific credit risk. The requirement to review, and update if there is a change, cash flow assumptions at least annually is expected to change the pattern of earnings being recognized. Adoption will also significantly expand the Company’s disclosures, and will impact systems, processes, and controls. While the requirements of the new guidance represent a material change from existing GAAP, the accounting adoption had no economic impact on the cash flows of our business nor influence our business model of providing basic mortality and longevity protection-oriented products to the underserved senior market. In addition, it did not impact our statutory earnings, statutory capital, nor our capital management philosophies. The following tables present the effect of the adoption of ASU 2018-12 on selected consolidated balance sheet data for the fiscal years ended March 31, 2023 and 2022.     Year Ended March 31,     2023   2022     (Unaudited)     (In thousands) Total Assets         Prior to adoption $   18,124,648 $   17,299,581 Effect of adoption:         Derecognition of shadow reserves   (25,141)   26,131 Re-measurement due to discount rate   –   – Other adjustments   1,227   1,471 Subtotal $   (23,914) $   27,602           After adoption $   18,100,734 $   17,327,183       Year Ended March 31,     2023   2022     (Unaudited)     (In thousands) Total Liabilities         Prior to adoption $   11,596,313 $   11,347,089 Effect of adoption:         Derecognition of FIT on shadow reserves   (5,280)   5,488 Re-measurement due to discount rate   (1,626)   87,258 Re-measurement due to discount rate FIT   342   (18,324) Other adjustments   6,794   8,511 Subtotal $   230 $   82,933           After adoption $   11,596,543 $   11,430,022       Year Ended March 31,     2023   2022     (Unaudited)     (In thousands) Accumulated other comprehensive income (loss)         Prior to adoption $   (267,046) $   46,384 Effect of adoption:         Derecognition of shadow reserves   (19,861)   20,644 Re-measurement due to discount rate   1,626   (87,258) Re-measurement due to discount rate FIT   (342)   18,324 Other adjustments   –   – Subtotal $   (18,577) $   (48,290)           After adoption $   (285,623) $   (1,906)       Year Ended March 31,     2023   2022     (Unaudited)     (In thousands) Total Stockholders' equity         Prior to adoption $   6,528,335 $   5,952,492 Effect of adoption:         Derecognition of shadow reserves and FIT   (19,861)   20,644 Re-measurement due to discount rate and FIT   1,284   (68,934) Other adjustments   (5,567)   (7,042) Subtotal $   (24,144) $   (55,332)           After adoption $   6,504,191 $   5,897,160 The following table presents the Company’s consolidated balance sheet, both before and after the Transition date.     April 1, 2021   March 31, 2021     (Unaudited)     (In thousands)           Deferred policy acquisition costs, net $   131,187 $   89,749 Total assets   14,693,044   14,651,606 Policy benefits and losses, claims and loss expenses payable   1,040,951   909,701 Deferred income taxes, net   1,182,123   1,199,280 Total liabilities   9,846,608   9,732,515 Accumulated other comprehensive income   42,319   106,857 Retained earnings   5,017,451   5,025,568 Total stockholders' equity   4,846,436   4,919,091 Total liabilities and stockholders' equity   14,693,044   14,651,606 The impacts from the adoption of ASU 2018-12 on the Company’s previously reported results included in these financial statements are as follows: Condensed Consolidated Balance Sheet     Year Ended March 31, 2023     As previously reported   Adoption impact   As adjusted     (Unaudited)     (In thousands)               Deferred policy acquisition costs, net $   152,377   (23,914) $   128,463 Total assets   18,124,648   (23,914)   18,100,734 Policy benefits and losses, claims and loss expenses payable   875,034   5,168   880,202 Deferred income taxes, net   1,334,427   (4,938)   1,329,489 Total liabilities   11,596,313   230   11,596,543 Accumulated other comprehensive loss   (267,046)   (18,577)   (285,623) Retained earnings   7,008,715   (5,567)   7,003,148 Total stockholders' equity   6,528,335   (24,144)   6,504,191 Total liabilities and stockholders' equity   18,124,648   (23,914)   18,100,734 Condensed Consolidated Statement of Operations     Quarter Ended June 30, 2022     As previously reported   Adoption impact   As adjusted     (Unaudited)     (In thousands)               Benefits and losses $   44,100   (4,343) $   39,757 Pretax earnings   441,056   4,343   445,399 Net earnings available to common stockholders   334,002   4,343   338,345 Basic and diluted earnings per share of Common Stock $   2.15   0.03 $   2.18 Basic and diluted earnings per share of Non-Voting Common Stock $   1.65   0.03 $   1.68   The following tables present the balances of and changes in deferred acquisition costs, future policy benefits and market risk benefits and balances amortized on a basis consistent with DAC on April 1, 2021 due to the adoption of ASU 2018-12 by Oxford.   Deferred Policy Acquisition Costs   Payout Annuities   Life Insurance   Health Insurance   Total     (Unaudited)     (In thousands)                   Balance, end of year March 31, 2021 $ 15,654 $ 64,552 $ 9,543 $ 89,749 Adjustments for removal of related balances in accumulated other comprehensive income   41,438   –   –   41,438 Adjusted balance, beginning of year April 1, 2021 $ 57,092 $ 64,552 $ 9,543 $ 131,187 Future Policy Benefit   Payout Annuities   Life Insurance   Health Insurance   Total     (Unaudited)     (In thousands)                   Balance, end of year March 31, 2021 $ 8,370 $ 310,311 $ 18,341 $ 337,022 Change in discount rate assumptions   2,307   115,978   4,847   123,132 Change in cash flow assumptions, effect of net premiums exceeding gross premiums   –   1,747   –   1,747 Change in cash flow assumptions, effect of decrease of the deferred profit liability   –   2,580   –   2,580 Adjusted balance, beginning of year April 1, 2021 $ 10,677 $ 430,616 $ 23,188 $ 464,481   Market Risk Benefits               Deferred Annuities                 (Unaudited)                 (In thousands)                   Balance, end of year March 31, 2021             $ 7,339 Adjustment for the difference between carrying amount and fair value, except for the difference due to instrument-specific credit risk               3,791 Adjusted balance, beginning of year April 1, 2021             $ 11,130 The following table presents the effect of transition adjustments on stockholders’ equity due to the adoption of ASU 2018-12 for Oxford.             Retained Earnings   Accumulated Other Comprehensive Loss             (Unaudited)             (In thousands)                   Liability for future policy benefits         $ (4,327) $ (123,132) Market risk benefits           (3,791)   – Deferred acquistion costs and related asset balances           –   41,438 Tax effect           –   17,156 Total         $ (8,118) $ (64,538) Recent Accounting Pronouncements In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842 – Common Control Arrangements (“ASU 2023-01”). ASU 2023-01, accounting for leasehold improvements, requires a lessee in a common-control lease arrangement to amortize leasehold improvements that it owns over the improvements  useful life to the common control group, regardless of the lease term, if the lessee continues to control the use of the underlying asset through a lease.  The amendment is effective for fiscal years beginning after December 15, 2023. We are currently in the process of evaluating the impact if any of the adoption of ASU 2023-01 on our financial statements.